About Protembis
Mitigating large brain lesions during TAVR. TAVR procedures can cause large brain infarcts, which may lead to procedural clinical stroke and an increased risk of future stroke, cognitive decline, and dementia.
Sectors & Market Categories
Company Details
Corporate & Operational Profile
Primary Industry
Biotech & Healthcare
Funding Stage
Series-B+
Global Headquarters
Undisclosed
Tracked Since
Oct 1, 2026
Web & Domain Identity
Official Website
protembis.com
Domain Registered Date
Oct 3, 2013
Social & Network Presence
X / Twitter Profile
Not linked
LinkedIn Corporate
Not linked
Company Milestones & Timeline
- Capital Raise
Raised $32,500,000 · Series-B+
startupintros.com
- Capital Raise
Raised $10,000,000 · Series-A
startupintros.com
- Milestone
Website domain registered
protembis.com
Investors & Backers
Investor firms and individual backers were not publicly disclosed in available round filings for Protembis.
Funding History
Series-B+
· Mar 26, 2024
$32,500,000 startupintros.com
Series-A
· Oct 26, 2018
$10,000,000 startupintros.com
Press Coverage & Sources
Recently Funded Biotech & Healthcare Startups
View allVitalls
vitalls.ai
Seed Abu Dhabi, United Arab Emirates · Oct 2026
Hexagon Bio
hexagonbio.com
Series-B+ Oct 2026
RefloDx
reflodx.com
Seed Kaysville, United States · Oct 2026
HeyVoli
heyvoli.com
Pre-Seed Bangalore, India · Oct 2026
CureBay
curebay.com
Series-B+ Bhubaneshwar, India · Oct 2026
4Tissue
4tissue.com
Series-A Ghent, Belgium · Oct 2026